Given Imaging First Quarter 2002 Revenues Exceed
$5.0 Million
YOQNEAM, Israel, April 16 /PRNewswire-FirstCall/ -- Given Imaging (Nasdaq: GIVN -
news) announced today that sales of its Given Diagnostic System and M2A® capsule
endoscope exceeded $5.0 million in the first quarter of 2002.
First Quarter Conference Call Details
Given Imaging plans to release first quarter 2001 financial results following the close of market
trading on Tuesday April 30, 2002. The Company will host a conference call on Wednesday,
May 1 at 10:00am Eastern time, which will be broadcast live on Given Imaging's website,
www.givenimaging.com
About Given Imaging
Given Imaging produces and markets the Given Diagnostic System, which features the M2A®
Capsule Endoscope, a fundamentally new approach to examining the gastrointestinal tract.
The system uses a disposable miniature video camera contained in a capsule that is ingested
by a patient and delivers high quality color images in a painless and noninvasive manner. The
test can be conducted while a patient continues normal daily activities. The system received
clearance from the FDA in August 2001 and received permission to affix the CE mark in May
2001. It is currently available in the USA, Canada, Europe, Brazil, Puerto Rico, Venezuela,
Mexico, Australia, New Zealand, and Israel. Many thousands of patients suffering from
diseases in the small intestine such as Crohn's, celiac disease, unexplained abdominal pain with
diarrhea, polyposis, intestinal tumors, iron deficiency anemia and obscure bleeding have
already benefited from this innovative technology. For more information, visit
www.givenimaging.com.
This press release contains forward-looking statements, including projections about our
business, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. For example, statements in the future tense, words such
as ``anticipates,'' ``estimates,'' ``expects,'' ``intends,'' ``plans,'' ``believes,'' ``intends'' and
words and terms of similar substance used in connection with any discussion of future
operating or financial performance identify such forward-looking statements. Those forward-looking statements are not
guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous
factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales,
marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency
exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our
product from healthcare payors, and other risks disclosed in our filings with the U.S. Securities Exchange Commission.
SOURCE: Given Imaging |
